The small company discount is real. Your $20M business won't trade at the same multiple as a $200M one.
When a headline says “healthcare businesses are trading at 6.45x EBITDA,” it sounds precise. But that number comes from S&P Capital IQ's analysis of all announced transactions — including Pfizer buying a biotech for $50B. It has limited relevance to a $15M clinic group in the midwest.
The small company discount is a well-documented phenomenon in M&A. Smaller businesses trade at lower multiples than their larger counterparts, for a set of reasons that are entirely rational from a buyer's perspective.
Why smaller businesses trade at a discount
The adjusted multiples by sector
| Sector | Market Multiple | SMB Adjusted | $5M EBITDA = |
|---|---|---|---|
| Healthcare | 6.45x | 4.0–5.5x | $20M–$27.5M |
| Telecom | 5.77x | 3.5–5.0x | $17.5M–$25M |
| Distribution | 8.26x | 5.0–7.0x | $25M–$35M |
| Consumer | 8.36x | 5.0–7.0x | $25M–$35M |
Source: S&P Capital IQ (market multiples) · SMB adjusted range applies 20–40% size discount · Ranges are illustrative, not valuations.
What this means for buyers
Understanding the discount is not about getting a “deal” — it's about paying the right price for the actual risk. A business that presents well on paper (clean books, stable revenue, growing market) deserves a premium over the bottom of the range. A business with customer concentration, a key person risk, or inconsistent financials belongs at the low end or below.
The job of professional diligence at this deal size is to put you in the right position on that range — with evidence, not intuition. Financial due diligence normalises the EBITDA so you're pricing the right number. Commercial due diligence quantifies the risks that move you up or down the multiple range.
Working out what a business is worth?
Tell me the sector, revenue, and EBITDA. I'll give you a first-principles view on the right multiple range — and what moves it.
Book a 30-Minute Call